Innovent Biologics, Inc.

Informe acción SEHK:1801

Capitalización de mercado: HK$64.7b

Innovent Biologics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Innovent Biologics has been growing earnings at an average annual rate of 19.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 30% per year.

Información clave

19.1%

Tasa de crecimiento de los beneficios

33.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 11.0%
Tasa de crecimiento de los ingresos30.0%
Rentabilidad financiera-10.3%
Margen neto-17.2%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14
Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01
Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Feb 28
There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Jan 12
Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

Dec 25
Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Sep 11
An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Jun 04
Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

May 14
Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27
Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Desglose de ingresos y gastos

Cómo gana y gasta dinero Innovent Biologics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:1801 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 247,457-1,2814,3342,280
31 Mar 246,831-1,1554,0932,196
31 Dec 236,206-1,0283,8512,112
30 Sep 235,612-1,1983,5942,366
30 Jun 235,018-1,3683,3362,620
31 Mar 234,787-1,7743,3812,745
31 Dec 224,556-2,1793,4262,871
30 Sep 224,562-2,4273,6332,697
30 Jun 224,568-2,6763,8402,523
31 Mar 224,419-2,7023,6332,423
31 Dec 214,270-2,7293,4262,323
30 Sep 214,536-2,0612,9812,170
30 Jun 214,801-1,3942,5362,018
31 Mar 214,323-1,1962,1571,935
31 Dec 203,844-9981,7781,851
30 Sep 202,765-1,3061,5071,642
30 Jun 201,686-1,6141,2361,432
31 Mar 201,367-1,6671,0921,363
31 Dec 191,048-1,7209481,295
30 Sep 19699-4,1257831,384
30 Jun 19351-6,5306181,472
31 Mar 19180-6,1514871,347
31 Dec 189-5,7713561,222
30 Sep 1839-3,0412481,014
30 Jun 1869-311139807
31 Mar 1872-437113709
31 Dec 1775-56288612
31 Dec 1629-50457385

Ingresos de calidad: 1801 is currently unprofitable.

Margen de beneficios creciente: 1801 is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 1801 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.1% per year.

Acelerando crecimiento: Unable to compare 1801's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 1801 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Rentabilidad financiera

Alta ROE: 1801 has a negative Return on Equity (-10.31%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado